KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Free Cash Flow (2016 - 2025)

Pacific Biosciences Of California has reported Free Cash Flow over the past 16 years, most recently at -$19.9 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$19.9 million for Q4 2025, up 38.23% from a year ago — trailing twelve months through Dec 2025 was -$113.9 million (up 46.33% YoY), and the annual figure for FY2025 was -$113.9 million, up 46.33%.
  • Free Cash Flow for Q4 2025 was -$19.9 million at Pacific Biosciences Of California, down from -$18.6 million in the prior quarter.
  • Over the last five years, Free Cash Flow for PACB hit a ceiling of -$17.3 million in Q2 2021 and a floor of -$98.4 million in Q1 2023.
  • Median Free Cash Flow over the past 5 years was -$45.4 million (2025), compared with a mean of -$50.0 million.
  • Biggest five-year swings in Free Cash Flow: tumbled 273.72% in 2022 and later soared 58.32% in 2025.
  • Pacific Biosciences Of California's Free Cash Flow stood at -$34.6 million in 2021, then tumbled by 89.49% to -$65.5 million in 2022, then grew by 8.99% to -$59.6 million in 2023, then soared by 45.85% to -$32.3 million in 2024, then skyrocketed by 38.23% to -$19.9 million in 2025.
  • The last three reported values for Free Cash Flow were -$19.9 million (Q4 2025), -$18.6 million (Q3 2025), and -$29.9 million (Q2 2025) per Business Quant data.